News today that Guardant Health, a Redwood City innovator lab focused on liquid biopsy, has raised a new round of funding for $360M. This brings its total fundraising effort to $550M.
Open access news coverage at Forbes here. And at MedCityNews here.
Investors include SoftBank, T Rowe Price, Temasek, Khosla Ventures, Lightspeed, Orbimed, and 8VC.
Projects include liquid biopsy for driver gene diagnostics in patients with solid cancers and Project Lunar, which will focus on detecting the existence or reappearance of residual disease.
Other recent fundraising in this space includes $60M for startup Freeome and $900M for Illumina spinout Grail.